Yes, Depo-Provera users were not adequately warned about meningioma risk. In December 2025, the FDA approved a new safety label for Depo-Provera warning specifically about cases of meningioma following repeated use of the contraceptive. This warning came after two major scientific studies—one published in JAMA Neurology in September 2025 and another in BMJ in March 2024—documented a significantly elevated risk of brain tumors in women using the injection, with some research showing a fivefold increased risk with prolonged use. The label language states: “Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.” Despite these documented risks, lawsuits allege that Pfizer, the manufacturer, knew or should have known about the connection but failed to warn users adequately for years.
More than 5,800 women have filed claims in the consolidated litigation (MDL-3140) as of July 2026, many reporting they were never informed of this specific brain tumor risk when they received Depo-Provera injections. One plaintiff used the injection from 2005 to 2021—16 years—with no warning about meningioma risk before her diagnosis. The first lawsuit was filed in October 2024, triggering a mass tort litigation that moved rapidly through the federal court system in Florida. In June 2026, Pfizer announced a settlement agreement in principle with plaintiffs’ counsel, though the terms remain confidential as of July 2026. The case represents a significant development in pharmaceutical liability, as it involves a drug that millions of women have used for contraception and that was previously considered a standard birth control option without notable cancer risks.
Table of Contents
- What Does the Research Actually Show About Depo-Provera and Meningioma Risk?
- The FDA’s Delayed Action and Why the Warning Came So Late
- The Legal Claims and What Plaintiffs Allege
- Estimating Potential Compensation and Settlement Values
- Eligibility Criteria and Documentation Requirements
- Who Had Meningioma Risk and Who Didn’t
- What Happens if the Settlement Falls Through
What Does the Research Actually Show About Depo-Provera and Meningioma Risk?
The clearest evidence comes from a September 2025 study in JAMA Neurology conducted by researchers at Cleveland Clinic and Case Western Reserve University. These researchers analyzed data from over 10 million women across 68 U.S. healthcare organizations over two decades (2004-2024) and found that women using Depo-Provera had a relative risk of 2.43 (with a 95% confidence interval of 1.77-3.33) for meningioma diagnosis compared to women not using the drug. This means that Depo-Provera users were more than twice as likely to develop meningiomas than non-users. The risk was highest in women who used the injection for more than four years or who started use after age 31, suggesting that duration and timing matter significantly. An earlier study published in BMJ on March 27, 2024, analyzed data on 108,366 women, including 18,061 with meningiomas, and found an odds ratio of 5.55—a fivefold increased risk—when women used Depo-Provera for one year or longer.
This more dramatic finding highlights the cumulative nature of the risk: the longer the exposure, the higher the likelihood of developing a meningioma. Importantly, researchers found that other contraceptives—combined oral birth control pills, IUDs, progestin-only pills, and subdermal implants—showed no increased meningioma risk. This pattern suggests that Depo-Provera specifically, not progestin use in general, carries this brain tumor association. The difference between a 2.43x risk and a 5.55x risk illustrates how medical research evolves and sometimes produces varying results depending on methodology, population studied, and definitions used. Both studies, however, point in the same direction: Depo-Provera users face a measurably elevated meningioma risk, particularly with prolonged use. For a woman who used Depo-Provera for ten years, the cumulative exposure was substantially higher than for a woman who used it for one year, and the research suggests her risk profile was also notably different.
The FDA’s Delayed Action and Why the Warning Came So Late
The FDA approved the meningioma warning label on December 12, 2025, more than a year after the BMJ study made its findings public and months after the JAMA Neurology study in September 2025. What’s striking is that Pfizer had actually requested a similar warning earlier—in 2024—and the FDA rejected it at that time. Pfizer resubmitted the warning request in June 2025 and received approval in December 2025, suggesting there was internal disagreement within the FDA about the sufficiency of evidence or the appropriate regulatory action. This timeline raises questions about why the warning took so long when the scientific evidence was substantial by 2024.
Women who received Depo-Provera injections between 2024 and December 2025 did so with no FDA-approved warning about meningioma risk on the drug’s label, even though peer-reviewed research had documented the association. The delay matters because it represents a window during which prescribers and patients could not rely on an official FDA warning to inform their decisions about whether to use or continue using the drug. one significant limitation of the FDA approval process is that it acts on evidence that manufacturers submit or that regulators proactively review, but there is no requirement that manufacturers automatically update labels the moment new research appears in medical journals. The label change required formal submissions, FDA review, and internal deliberation—processes that can take months even when the underlying science is clear.
The Legal Claims and What Plaintiffs Allege
The litigation centers on a failure-to-warn claim: plaintiffs argue that Pfizer was aware of or should have been aware of the meningioma risk but did not include adequate warnings on the Depo-Provera label or in communications to healthcare providers and patients. The first lawsuit was filed in October 2024, likely filed shortly after the BMJ study results became widely discussed in medical and legal circles. Within months, the litigation had grown to include over 5,830 individual claims consolidated into MDL-3140 (Multidistrict Litigation No. 3140) in the U.S. District Court for the Northern District of Florida, with Judge M.
Casey Rodgers overseeing the proceedings. Originally, the first bellwether case (a pilot case intended to test the legal arguments and evidence) was scheduled for trial on December 7, 2026. However, on June 15, 2026—months before that trial date—Pfizer announced that it had reached a “global agreement in principle” with plaintiffs’ counsel. That announcement led to the vacating of the December trial date, though the settlement terms were not disclosed publicly and remain confidential as of July 2026. The speed of the settlement—from over 5,800 consolidated claims to a settlement announcement in less than nine months—suggests that both sides may have concluded that trials would be costly and that the evidence of risk was substantial enough to justify resolution. The remaining bellwether cases, with five pilot cases selected for potential trials beginning in January 2027, remain in the litigation schedule in case the settlement fails to finalize or if disputes arise during the settlement administration process.
Estimating Potential Compensation and Settlement Values
The actual settlement amount and payout structure have not been publicly disclosed as of July 2026, but various plaintiff attorneys have offered speculative estimates based on comparable mass tort settlements. Some estimates range from $75,000 to over $1.5 million per individual claimant, though these figures are rough projections and not official settlement terms. The wide range reflects the uncertainty involved in predicting how settlements will value different cases—factors like severity of the meningioma diagnosis, age of the claimant at diagnosis, duration of Depo-Provera use, and causation evidence can all affect individual case valuations. To put these estimates in context, comparable pharmaceutical mass tort settlements have varied widely.
A bladder cancer litigation involving a certain class of diabetes drugs settled for amounts in the hundreds of thousands per claimant in some cases and lower amounts in others, depending on proof of injury. The Depo-Provera settlement’s structure—whether it will use a claims administrator with different payout tiers based on injury severity or take another approach—will significantly influence what individual claimants ultimately receive. One important distinction is between the gross settlement amount (the total fund) and the per-claimant distribution (what individuals actually receive after attorneys’ fees, administrative costs, and claims processing). A settlement with a larger gross amount but thousands of eligible claimants may ultimately pay less per person than a smaller settlement with fewer claims. The confidentiality of the Pfizer settlement terms prevents claimants from knowing the actual numbers until the settlement is finalized and disclosed.
Eligibility Criteria and Documentation Requirements
Although the formal settlement terms are confidential, claimants in similar pharmaceutical litigation typically must meet certain criteria: proof that they used Depo-Provera, a diagnosis of meningioma, medical records showing the diagnosis and treatment, and often a medical or scientific expert opinion linking the drug use to the tumor development. The timeline may also matter—claims involving use before a certain date (such as when research first documented the risk) may be valued differently than claims involving more recent use. One limitation that deserves emphasis is the challenge of proving causation in individual cases. While the epidemiological studies show increased risk at the population level, proving that a specific individual’s meningioma was caused by Depo-Provera rather than by chance is more difficult.
Each case requires medical records, imaging, pathology reports, and expert analysis. Claimants without comprehensive medical documentation from the time of diagnosis may face challenges substantiating their claims, and some cases may be denied or valued lower if the evidence of causation is weaker. The settlement administration will likely establish a claims process with deadlines, documentation requirements, and an appeals process for denied claims. Claimants who cannot locate old medical records or who have incomplete treatment histories may find their claims delayed or subject to challenge. Women who received Depo-Provera through community health clinics or international providers may have additional documentation hurdles.
Who Had Meningioma Risk and Who Didn’t
The research shows that the meningioma risk was not uniform across all Depo-Provera users. Women who used the injection for more than four years had substantially higher risk than women who used it briefly. Women who started Depo-Provera use after age 31 had higher risk than younger users, though the reason for this age-related difference is not entirely clear from the published research—it could reflect accumulated exposure, biological factors, or detection bias.
Women who used other contraceptives (oral birth control pills, IUDs, hormonal implants) did not show the same elevated meningioma risk, indicating that the risk is specific to Depo-Provera’s formulation or delivery mechanism. Conversely, a woman who received three or four Depo-Provera injections over a year or two and then switched to another method would have substantially lower risk than a woman who received injections continuously for ten years. This dose-response relationship—higher risk with greater cumulative exposure—is consistent with other drug-induced adverse effects and strengthens the causal inference from the research. However, it also means that individual risk assessment requires knowing not just whether someone used Depo-Provera, but for how long and when they used it relative to meningioma diagnosis.
What Happens if the Settlement Falls Through
Although Pfizer and plaintiffs’ counsel reached an agreement in principle in June 2026, the settlement still requires finalization of terms, court approval, and completion of the claims process. If negotiations break down or if the court rejects the settlement as inadequate, the litigation would proceed to trial. The five bellwether cases currently scheduled for January 2027 (if the settlement fails) would move forward as pilot cases intended to establish liability, causation, and damages principles that would then apply to remaining claims.
A trial verdict in favor of plaintiffs could potentially result in higher per-claimant payouts than a settlement, but it would also introduce risk—a jury verdict could go either way, and appeals could extend resolution for years. Conversely, a defense verdict would eliminate any recovery for most claimants except those with particularly strong evidence. The settlement, though confidential, likely represents both parties’ calculation that resolution was preferable to the uncertainty and cost of continued litigation through trial.
- —